LPTX - Leap Therapeutics GAAP EPS of -$0.32 misses by $0.23
2023-05-15 10:17:30 ET
- Leap Therapeutics press release ( NASDAQ: LPTX ): Q1 GAAP EPS of -$0.32 misses by $0.23 .
- Net Loss was $41.9 million for the first quarter 2023, compared to $10.4 million for the same period in 2022.
-
Cash and cash equivalents totaled $102.0 million at March 31, 2023. Research and development incentive receivables totaled $2.3 million at March 31, 2023.
For further details see:
Leap Therapeutics GAAP EPS of -$0.32 misses by $0.23